Wyeth Pushes Back NDA Filing Timeline For Aprela For Vasomotor Symptoms
This article was originally published in The Pink Sheet Daily
Executive Summary
Filing for Aprela is now targeted for Q2 2008 rather than the end of the year.
You may also be interested in...
Beyond Hormone Therapy: Signs Of Life In Pipeline For Menopausal Women
Conditions associated with menopause represent a huge market, yet the R&D pipeline has long been slim, despite the well-known drawbacks of marketed hormone replacement therapies. But new approaches with a tissue-selective estrogenic effect are emerging: Shionogi’s Osphena for menopause-related sexual dysfunction broke the long drought in NME approvals, and Pfizer’s broad NDA for bazedoxifene/conjugated estrogens is under review. Emerging companies like EndoCeutics are exploring new hormonal approaches.
Wyeth To Re-Submit Viviant This Year, Expects FDA Advisory Review
Merged Pfizer/Wyeth will likely have to choose between Viviant and Fablyn.
Wyeth To Re-Submit Viviant This Year, Expects FDA Advisory Review
Merged Pfizer/Wyeth will likely have to choose between Viviant and Fablyn.